SOUTH SAN FRANCISCO, Calif., Aug. 6, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, August 13, 2012 at 9:00AM PDT, to discuss second quarter 2012 financial results and provide a business update.
| Conference call details: | |
| Date: | Monday, August 13, 2012 |
| Time: | 12:00pm EDT, 9:00am PDT |
| Dial-in (U.S. and Canada): | (877) 681 – 1326 |
| Dial-in (International): | (708) 290 – 1158 |
| Web cast: | www.talontx.com |
An archived version of the webcast will also be available via the company's website following the call.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon's lead product candidate is Marqibo® which is being developed for the treatment of acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma. Marqibo has a PDUFA date of August 12, 2012 regarding accelerated approval for treatment of ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
In addition to Marqibo, the Company has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
The Talon Therapeutics, Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=3290